Melanoma (January 2015) | Targeted Therapies: Melanoma

Combined Inhibition of BRAF and MEK Improves Progression-Free Survival in BRAF-Mutated Melanoma

January 10, 2015

Clinical Articles

Reported results from the coBRIM study have shown that combining the BRAF inhibitor vemurafenib with cobimetinib, a MEK inhibitor, increases progression-free survival (PFS) in patients with BRAF-mutated advanced melanoma compared with vemurafenib alone.

An Immunostimulatory, Targeted Cytotoxic Medication for Skin Cancer: Aviscumine

January 09, 2015

Clinical Articles

Cytavis Biopharma GmbH, a Germany-based pharmaceutical company, is developing a natural protein, aviscumine (CY-503), as an immunostimulatory agent to improve response to immunotherapeutic treatment of melanoma.